NCT03017833View on ClinicalTrials.gov

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 12, 2018

Primary Completion Date

December 21, 2022

Study Completion Date

December 21, 2022

Conditions
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Metformin

Given PO

OTHER

Pharmacological Study

Ancillary studies

DRUG

Sapanisertib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03017833 - Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers | Biotech Hunter | Biotech Hunter